Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Average Rating of “Buy” by Brokerages

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) have earned an average rating of “Buy” from the ten brokerages that are covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $46.4286.

AAPG has been the subject of several analyst reports. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Deutsche Bank Aktiengesellschaft initiated coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 price objective for the company. B. Riley Financial initiated coverage on Ascentage Pharma Group International in a research report on Wednesday. They set a “buy” rating and a $45.00 price objective for the company. Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday. Finally, BTIG Research reaffirmed a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research report on Monday, April 13th.

Ascentage Pharma Group International Stock Up 2.9%

Shares of NASDAQ AAPG opened at $17.60 on Friday. Ascentage Pharma Group International has a twelve month low of $16.92 and a twelve month high of $48.45. The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The stock has a fifty day simple moving average of $22.10 and a 200-day simple moving average of $24.75.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The firm had revenue of $24.72 million during the quarter. As a group, sell-side analysts expect that Ascentage Pharma Group International will post -0.96 earnings per share for the current year.

Institutional Trading of Ascentage Pharma Group International

A number of large investors have recently made changes to their positions in AAPG. Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International during the 3rd quarter valued at approximately $383,000. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International during the 2nd quarter valued at approximately $391,000. XY Capital Ltd raised its stake in shares of Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after buying an additional 12,530 shares in the last quarter. Finally, UBS Group AG raised its stake in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares in the last quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.